Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benjamin Besse

Showing results (151-160 of 512) with videos related to

Pageof 52
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 3, 2008
Mitogen-activated protein kinase activation in lung adenocarcinoma: a comparative study between ever smokers and never smokersGiannis Mountzios, David Planchard, Benjamin Besse, et al.
Journal of Immunology (Baltimore, Md. : 1950)|March 1, 2015
CD8+CD103+ tumor-infiltrating lymphocytes are tumor-specific tissue-resident memory T cells and a prognostic factor for survival in lung cancer patientsFayçal Djenidi, Julien Adam, Aïcha Goubar, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|September 25, 2020
Can radiation-recall predict long lasting response to immune checkpoint inhibitors?Eric Deutsch, Benjamin Besse, Jérôme Le Pavec, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 18, 2010
Phase 1b study of dulanermin (recombinant human Apo2L/TRAIL) in combination with paclitaxel, carboplatin, and bevacizumab in patients with advanced non-squamous non-small-cell lung cancerJean-Charles Soria, Egbert Smit, David Khayat, et al.
Frontiers in Immunology|February 1, 2024
HLA-DR expression in melanoma: from misleading therapeutic target to potential immunotherapy biomarkerKarim Amrane, Coline Le Meur, Benjamin Besse, et al.
Plos One|August 23, 2017
Crystal digital droplet PCR for detection and quantification of circulating EGFR sensitizing and resistance mutations in advanced non-small cell lung cancerCécile Jovelet, Jordan Madic, Jordi Remon, et al.
Journal of Thoracic Disease|June 29, 2018
Do immune checkpoint inhibitors need new studies methodology?Roberto Ferrara, Sara Pilotto, Mario Caccese, et al.
Journal of Personalized Medicine|June 2, 2021
Lincp21-RNA as Predictive Response Marker for Preoperative Chemoradiotherapy in Rectal CancerJose Carlos Benitez, Marc Campayo, Tania Díaz, et al.
Acta Cytologica|December 5, 2012
Circulating tumor cells in lung cancerRachel Young, Emma Pailler, Fanny Billiot, et al.
Bulletin Du Cancer|December 5, 2014
[Focus on targeting the Ras-MAPK pathway: the Mek inhibitors]Capucine Baldini, Boris Duchemann, Antoine Hollebecque, et al.
Pageof 52

Showing results (151-160 of 512) with videos related to

Sort By:
Pageof 52
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 3, 2008
Mitogen-activated protein kinase activation in lung adenocarcinoma: a comparative study between ever smokers and never smokersGiannis Mountzios, David Planchard, Benjamin Besse, et al.
Journal of Immunology (Baltimore, Md. : 1950)|March 1, 2015
CD8+CD103+ tumor-infiltrating lymphocytes are tumor-specific tissue-resident memory T cells and a prognostic factor for survival in lung cancer patientsFayçal Djenidi, Julien Adam, Aïcha Goubar, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|September 25, 2020
Can radiation-recall predict long lasting response to immune checkpoint inhibitors?Eric Deutsch, Benjamin Besse, Jérôme Le Pavec, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 18, 2010
Phase 1b study of dulanermin (recombinant human Apo2L/TRAIL) in combination with paclitaxel, carboplatin, and bevacizumab in patients with advanced non-squamous non-small-cell lung cancerJean-Charles Soria, Egbert Smit, David Khayat, et al.
Frontiers in Immunology|February 1, 2024
HLA-DR expression in melanoma: from misleading therapeutic target to potential immunotherapy biomarkerKarim Amrane, Coline Le Meur, Benjamin Besse, et al.
Plos One|August 23, 2017
Crystal digital droplet PCR for detection and quantification of circulating EGFR sensitizing and resistance mutations in advanced non-small cell lung cancerCécile Jovelet, Jordan Madic, Jordi Remon, et al.
Journal of Thoracic Disease|June 29, 2018
Do immune checkpoint inhibitors need new studies methodology?Roberto Ferrara, Sara Pilotto, Mario Caccese, et al.
Journal of Personalized Medicine|June 2, 2021
Lincp21-RNA as Predictive Response Marker for Preoperative Chemoradiotherapy in Rectal CancerJose Carlos Benitez, Marc Campayo, Tania Díaz, et al.
Acta Cytologica|December 5, 2012
Circulating tumor cells in lung cancerRachel Young, Emma Pailler, Fanny Billiot, et al.
Bulletin Du Cancer|December 5, 2014
[Focus on targeting the Ras-MAPK pathway: the Mek inhibitors]Capucine Baldini, Boris Duchemann, Antoine Hollebecque, et al.
Pageof 52